Loureirin B analogs mitigate oxidative stress and confer renal protection

Diabetic kidney disease (DKD) is a microvascular complication of diabetes with high morbidity and mortality, necessitating effective treatment. In this study, the Loureirin B analogue (LB-A) was utilized to treat DKD in mice. The results demonstrated that LB-A effectively prevent the progression of DKD in mice, significantly lowering fasting blood glucose levels and reducing proteinuria levels. Additionally, there was a significant decrease in oxidase content in the kidneys of mice, accompanied by an increase in antioxidant oxidase content, resulting in a decrease in ROS levels, mitigating oxidative stress state through modulation of Cxcl1. Cell experiments further confirmed that reducing Cxcl1/Cxcr2 axis activation prevented the onset of DKD induced by high glucose exposure and affected the therapeutic effect of LB-A as well. These findings provide evidences to support that LB-A may mitigate oxidative stress by modulating the Cxcl1 signaling pathway, thereby contributing to renal protection in the context of DKD treatment.